• Gbolahan Olatunji, Emmanuel Kokori, Ismaila Ajayi Yusuf, Olumide Akinmoju, Timilehin Isarinade, Rosemary Komolafe, Aminat Akinoso, Adeola Akinboade, Osadebamwen Osaghae, Muili Abdulbasit, and Nicholas Aderinto.
• Faculty of Clinical Sciences, University of Ilorin, Ilorin, Nigeria.
• Medicine (Baltimore). 2023 Dec 29; 102 (52): e36793e36793.

AbstractBreast cancer remains a significant global health challenge, necessitating innovative therapeutic strategies. This review synthesizes findings from multiple studies investigating the safety profile and efficacy of the AE37 human epidermal growth factor receptor 2 (HER2)-targeted vaccine, offering insights into its potential role in breast cancer immunotherapy. A systematic search of electronic databases, including PubMed, MEDLINE, Scopus, and Web of Science, was conducted to identify relevant articles published up to October 2023. The search strategy utilized a combination of keywords, including "AE37 HER2 vaccine," "breast cancer recurrence prevention," and related terms. Boolean operators (AND, OR) were employed to refine the search. The AE37 vaccine exhibited a favorable safety profile across all studies, with minimal adverse effects reported. Efficacy outcomes varied, with promising trends observed in specific breast cancer subgroups, such as advanced-stage, HER2 under-expressed, and triple-negative breast cancer patients. Subgroup analyses suggested potential benefits, emphasizing the need for precise patient stratification. While the AE37 HER2-targeted vaccine demonstrates a promising safety profile and potential efficacy in specific breast cancer subgroups, an understanding requires addressing identified limitations and advancing research in nuanced directions. This paper provides a foundation for navigating the complex landscape of breast cancer immunotherapy with the AE37 vaccine.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

29 keywords...

hide…